Nachrichten zur AstraZeneca PLC Aktie

Think Its Too Late to Buy Tempus AI? Heres the Biggest Reason Why Theres Still Time.

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like theyre standing on a dock watching…

Total Voting Rights

1 May 2025 Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct Authoritys Disclosure…

ROUNDUP 2: Astrazeneca droht Millionenstrafe in China - Aktie holt Verluste auf

(neu: Schlusskurs) CAMBRIDGE (dpa-AFX) - Beim Pharmakonzern Astrazeneca wird ein unerwartet starker Gewinnsprung zum Jahresstart durch…

ROUNDUP 2: Astrazeneca droht Millionenstrafe in China - Aktie holt Verluste auf

(neu: Schlusskurs) CAMBRIDGE (dpa-AFX) - Beim Pharmakonzern Astrazeneca wird ein unerwartet starker…

ROUNDUP: Astrazeneca droht Millionenstrafe in China - Aktie verliert nach Zahlen

CAMBRIDGE (dpa-AFX) - Beim Pharmakonzern Astrazeneca wird ein unerwartet starker Gewinnsprung zum Jahresstart durch eine…

ROUNDUP: Astrazeneca droht Millionenstrafe in China - Aktie verliert nach Zahlen

CAMBRIDGE (dpa-AFX) - Beim Pharmakonzern Astrazeneca wird ein unerwartet starker Gewinnsprung zum Jahresstart durch eine drohende Millionenstrafe in China…

AstraZeneca PLC 2025 Q1 - Results - Earnings Call Presentation

…

AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors

The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the…

FTSE 100 flat amid HSBC, BP and AstraZeneca earnings updates

The FTSE 100 crept into positive territory in early trade on Tuesday before turning marginally negative as investors digested a…

AstraZeneca shares fall as revenue miss tempers strong Q1 earnings By Investing.com

AstraZeneca shares fall as revenue miss tempers strong Q1 earnings…

Pharmahersteller Astrazeneca bleibt auch zum Jahresstart auf Wachstumskurs

CAMBRIDGE (dpa-AFX) - Beim Pharmakonzern Astrazeneca florieren weiterhin die Geschäfte insbesondere mit Krebsmedikamenten und biotechnologisch…

The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS

Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS are included in this Analyst Blog.…

Massive Investment in US Manufacturing Triggers Wave of Career Opportunities

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca executive and Eli Lilly and…

Tempus AI: Deal mit Pharma-Riesen – Aktie geht steil

Für den AKTIONÄR ist klar: Künstliche Intelligenz (KI) wird auch in der Forschung und Entwicklung von Medikamenten mittel- bis langfristig…

Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now?

Amid a bullish backdrop for the broader market, Tempus AI (NASDAQ: TEM) stock is posting big gains Wednesday. The companys…

Why Tempus AI Stock Is Skyrocketing Today

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain…

Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, Pathos

Tempus AI (NASDAQ:TEM) said on Wednesday it has signed multi-year strategic collaborations with AstraZeneca (AZN.L) and Pathos AI to co-develop…

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

The latest trading day saw Astrazeneca (AZN) settling at $67.87, representing a +1.45% change from its previous close.…

AstraZeneca rejoins leading U.S. drug lobby group after two-year absence

AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and Manufacturers…

ANALYSE-FLASH: Goldman belässt Astrazeneca auf 'Buy' - Ziel 15318 Pence

NEW YORK (dpa-AFX Broker) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca mit…

2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever

Equities are down this year because of Donald Trumps trade policies. The 47th U.S. president decided to impose steep tariffs…

Astrazeneca Aktie: Details zum strategischen Plan

Trotz aktueller Schwächephase halten Analysten an Kaufempfehlungen fest - Dividendenankündigung und Quartalszahlen im Fokus. Die AstraZeneca-Aktie zeigt sich diese Woche…

The Zacks Analyst Blog AbbVies, Rinvoq and AstraZenecas and Novartis

AbbVies, Rinvoq and AstraZenecas and Novartis are included in this Analyst Blog.…

Result of AGM

11 April 2025 Results of Annual General Meeting held on 11 April 2025 AstraZeneca PLC announced the results of the voting at…

Gothenburg - a launch pad for health innovators

As the Nordic region’s largest healthcare market and a leading life science nation, Sweden is an attractive environment for healthtech…

Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs

The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly…

Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today

Might the tariff risk for pharmaceutical stocks be less than you think?…

3 No-Brainer Growth Stocks to Buy for Less Than $100

Dont let the sell-off in the markets scare you off: Now may be an ideal time to buy stocks. Even…

Astrazeneca (AZN) Stock Moves -1.35%: What You Should Know

The latest trading day saw Astrazeneca (AZN) settling at $64.90, representing a -1.35% change from its previous close.…

AstraZenecas Innovation Ecosystem: From Blockbusters To The Next Generation Of Therapy

…

AstraZenecas metastatic breast cancer treatment gets EU nod

…

Imfinzi approved in EU for AEGEAN

04 April 2025 Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer  Approval based on AEGEAN Phase III trial…

Enhertu approved in EU in post-ET breast cancer

04 April 2025 Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer…

Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Markets Swoon on Thursday

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the…

UK pharma escapes worst of Trump tariffs (for now) but uncertainty may keep pressure on shares

International pharma stocks GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) may have dodged a bullet under Donald Trump’s sweeping new tariff...…

AstraZeneca and GSK shares rise on possible escape from new US tariffs

UK pharmaceutical giants AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) shares both avoided the wider sell-off on Thursday morning on hopes that...…

Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up

AstraZenecas new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.…

Calquence recommended for EU approval in 1L MCL

31 March 2025 Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line…

Imfinzi approved in the US for bladder cancer

31 March 2025 Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer  Based on NIAGARA Phase III…

AstraZenecas Imfinzi gains additional indication for bladder cancer

…

2 Surefire Dividend Stocks That Could Pay You for Life

Dividend investing is an excellent strategy for (at least) two reasons. Companies that can provide consistent payouts generally have robust…

Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet

The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street…

Astrazeneca (AZN) Stock Moves -0.45%: What You Should Know

In the most recent trading session, Astrazeneca (AZN) closed at $72.72, indicating a -0.45% shift from the previous trading day.…

Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead

The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities broadly…

AstraZeneca to invest $2.5bn in drugs research and manfacturing in Beijing

Pharmaceutical company will invest money over five years in ‘strategic partnership’ with the city’s authorities…

Astrazeneca Aktie: Marktbewegung vorausgesehen?

Der britische Pharmakonzern baut seine Präsenz im chinesischen Markt mit einem 2,5-Milliarden-Dollar Forschungszentrum in Peking aus, was Anleger vorerst skeptisch…

AstraZeneca details $2.5B investment in Chinas political center, funding R&D center, biotech pacts

AstraZeneca has shown its commitment to China amid investigations into its executives and activities,…

AstraZeneca to invest $2.5 billion in Beijing hub as it seeks to move on from China probes

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in the…

AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals By Reuters

AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals…

British pharma giant AstraZeneca to invest $2.5 billion in new China hub

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing,…